Key publications

Golebiewska A*, Hau A-C *, Oudin A *, Stieber D, Yabo Y A, Baus V, Barthelemy V, Klein E, Bougnaud S, Keunen O, Wantz M, Michelucci A, Neirinckx V, Muller A, Kaoma T, Nazarov P V, Azuaje F, de Falco A, Flies B, Poovathingal S, Arns T, Grzyb K, Mock A, Herold-Mende C, Steino A, Brown D, May P, Miletic H, Noushmehr H, Kwon Y-J, Jahn W, Klink B, Tanner G, Stead LF, Mittelbronn M, Skupin A, Hertel F, Bjerkvig R and Niclou SP; Primary and recurrent glioma patient-derived orthotopic xenografts (PDOX) represent relevant patient avatars for precision medicine; Acta Neuropathologica Oct 2020   | PubMed

Fritah S, Muller A, Jiang W, Mitra R, Sarmini M, Dieterle M, Golebiewska A, Ye T, Van Dyck E, Herold-Mende C, Zhao Z, Azuaje F, Niclou SP.; Temozolomide-induced RNA interactome uncovers novel lncRNA regulatory loops in glioblastoma. Cancers. 2020;12(9). | PubMed

White K, Connor K, Clerkin J, Murphy BM, Salvucci M, O'Farrell AC, Rehm M, O'Brien D, Prehn JHM, Niclou SP, Lamfers MLM, Verreault M, Idbaih A, Verhaak R, Golebiewska A, Byrne AT; New hints towards a precision medicine strategy for IDH wild-type Glioblastoma. Ann Oncol. 2020 Sept 9  | PubMed

Barthel FP, …Niclou SP,…., Verhaak RGW; GLASS Consortium. Longitudinal molecular trajectories of diffuse glioma in adults. Nature. 2019 | PubMed

Neirinckx V, Hau AC, Schuster A, Fritah S, Tiemann K, Klein E, Nazarov PV, Matagne A, Szpakowska M, Meyrath M, Chevigné A, Schmidt MHH, Niclou SP.; The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in glioblastoma​. Neurooncol Adv. 2019 | PubMed

Dirkse A*, Golebiewska A*, Buder T, Nazarov P, Muller A, Poovathingal S, Brons NHC, Leite S, Sauvageot N, Sakrisijan D, Seyfried M, Fritah S, Stieber D, Michelucci A, Hertel F, Herold-Mende C, Azuaje F, Skupin A, Bjerkvig R, Deutsch A, Voss-Bohme A, Niclou SP. Stem cell-associated heterogeneity in glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment. Nature Communications. 2019 Apr 16;10(1):1787 | PubMed

Schuster A, Erasimus H, Fritah S, Nazarov PV, van Dyck E, Niclou SP*, Golebiewska A.* RNAi/CRISPR Screens: from a Pool to a Valid Hit. Trends Biotechnol. 2019 Jan;37(1):38-55 | PubMed

Sousa C, Golebiewska A, Poovathingal SK, Kaoma T, Pires-Afonso Y, Martina S, Coowar D, Azuaje F, Skupin A, Balling R, Biber K, Niclou SP, Michelucci A. Single-cell transcriptomics reveals distinct inflammation-induced microglia signatures. EMBO Rep. 2018 Nov;19(11) | PubMed

Meiser J, Schuster A, Pietzke M, Vande Voorde J, Athineos D, Oizel K, Burgos-Barragan G, Wit N, Dhayade S, Morton JP, Dornier E, Sumpton D, Mackay GM, Blyth K, Patel KJ, Niclou SP, Vazquez A. Increased formate overflow is a hallmark of oxidative cancer. Nature Communications 2018 Apr 10;9(1):1368. | PubMed

Fack F*, Tardito S*, Hochart G*, Oudin A, Zheng L, Fritah S, Golebiewska A, Nazarov PV, Bernard A, Hau AC, Keunen O, Leenders W, Lund-Johansen M, Stauber J, Gottlieb E, Bjerkvig R, Niclou SP. Altered metabolic landscape in IDH-mutant gliomas affects phospholipid, energy, and oxidative stress pathways. EMBO Mol Med. 2017 Oct 20;  | PubMed

Abdul Rahim SA, Dirkse A, Oudin A, Schuster A, Bohler J, Barthelemy V, Muller A, Vallar L, Janji B, Golebiewska A, Niclou SP. Regulation of hypoxia-induced autophagy in glioblastoma involves ATG9A. Br J Cancer. 2017 | PubMed

Bougnaud S, Golebiewska A, Oudin A, Keunen O, Harter PN, Mäder L, Azuaje F, Fritah S, Stieber D, Kaoma T, Vallar L, Brons NH, Daubon T, Miletic H, Sundstrøm T, Herold-Mende C, Mittelbronn M, Bjerkvig R, Niclou SP. Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma. Oncotarget. 2016 Mar 25  | PubMed

Fack F*, Espedal H*, Keunen O*, Golebiewska A, Obad N, Harter PN, Mittelbronn M, Bähr O, Weyerbrock A, Stuhr L, Miletic H, Sakariassen PØ, Stieber D, Rygh CB, Lund-Johansen M, Zheng L, Gottlieb E, Niclou SP, Bjerkvig R; Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. Acta Neuropathol. 2015 Jan; 129(1):115-31. | PubMed

Tardito S, Oudin A, Ahmed SU, Fack F , Keunen O , Zheng L , Miletic H , Sakariassen PO , Weinstock A, Wagner A, Lindsay SL , Hock AK , Barnett SC, Ruppin E, Morkve SH , Lund-Johansen M, Chalmers AJ, Bjerkvig R , Niclou SP and Gottlieb E . Glutamine Synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nature Cell Biology. 2015 Dec;17(12):1556-68 | PubMed

Demeure K, Fack F, Duriez E, Tiemann K, Bernard A, Golebiewska A, Bougnaud S, Bjerkvig R, Domon B, Niclou SP. Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma; Mol Cell Proteomics. 2015 Aug 4 | PubMed

Sanzey M, Abdul Rahim SA, Oudin A, Dirkse A, Kaoma T, Vallar L, Herold-Mende C, Bjerkvig R, Golebiewska A, Niclou SP. Comprehensive analysis of glycolytic enzymes as therapeutic targets in the treatment of glioblastoma; Plos One. 2015 May 1 | PubMed

Fritah S, Niclou SP, Azuaje F. Databases for lncRNAs: a comparative evaluation of emerging tools. RNA. 2014 Nov;20(11):1655-65. | PubMed

Stieber D*, Golebiewska A*, Evers L, Lenkiewicz E, Brons NH, Nicot N, Oudin A, Bougnaud S, Hertel F, Bjerkvig R, Vallar L, Barrett MT, Niclou SP; Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. Acta Neuropathol. 2014 Feb; 127(2):203-19. | PubMed  

Golebiewska A, Bougnaud S, Stieber D, Brons, NH, Vallar L, Hertel, F, Klink B, Schröck E, Bjerkvig, R, Niclou, SP; Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells. Brain. 2013 May; 136 | PubMed  

Johansson M*, Oudin A*, Tiemann K, Bernard A, Golebiewska A, Keunen O, Fack F, Stieber D, Wang B, Hedman H, Niclou SP; The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status​ Neurooncol. 2013 Sep | PubMed  

Keunen O, Johansson M, Oudin A, Sanzey M, Abdul Rahim SA, Fack F, Thorsen F, Taxt T, Bartos M, Jirik R, Miletic H, Wang J, Stieber D, Stuhr L, Moen I, Rygh CB, Bjerkvig R*, Niclou SP*. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3749-54. | PubMed

Golebiewska A, Brons NH, Bjerkvik R, Niclou SP; Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell. 2011 February 4, 2011 | PubMed

Rajcevic U, Petersen K, Knol JC, Loos M, Bougnaud S, Klychnikov O, Li KW, Pham TV, Wang J, Miletic H, Peng Z, Bjerkvig R, Jimenez CR, Niclou SP.; iTRAQ-based proteomics profiling reveals increased metabolic activity and cellular cross-talk in angiogenic compared with invasive glioblastoma phenotype​. Mol Cell Proteomics 2009 | PubMed

Niclou SP, Danzeisen C, Eikesdal HP, Wiig H, Brons NH, Poli AM, Svendsen A, Torsvik A, Enger PØ, Terzis JA, Bjerkvig R..; A novel eGFP-expressing immunodeficient mouse model to study tumor-host interactions​ FASEB J. 2008 | PubMed

 

*equal contributions

For all publications see: | PubMed